Spots Global Cancer Trial Database for neuroendocrine
Every month we try and update this database with for neuroendocrine cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours | NCT05605522 | Pancreatic Duct... Squamous Cell C... Colorectal Canc... Gastric Cancer Ewing Sarcoma NTSR1 Expressin... Neuroendocrine ... | [225]-FPI-2059 [111In]-FPI-205... | 18 Years - | Fusion Pharmaceuticals Inc. | |
| 68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors | NCT02038738 | Neuroendocrine Neuroendocrine ... Neuroendocrine ... Neuroendocrine ... Carcinoid Carcinoid Tumor Islet Cell Tumo... Apudoma | 68Ga-DOTATATE w... | 18 Years - | Ochsner Health System | |
| Natural History of Familial Carcinoid Tumor | NCT00646022 | Carcinoid | [18F]-DOPA | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization | NCT00434109 | Neuroendocrine ... Islet Cell Tumo... | Sunitinib malat... Hepatic Artery ... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer | NCT05005728 | Metastatic Cast... | vudalimab + car... vudalimab + ola... vudalimab monot... vudalimab + doc... vudalimab + cab... | 18 Years - | Xencor, Inc. | |
| 68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors | NCT02038738 | Neuroendocrine Neuroendocrine ... Neuroendocrine ... Neuroendocrine ... Carcinoid Carcinoid Tumor Islet Cell Tumo... Apudoma | 68Ga-DOTATATE w... | 18 Years - | Ochsner Health System | |
| Safety Study of Seneca Valley Virus in Patients With Solid Tumors With Neuroendocrine Features | NCT00314925 | Carcinoid Neuroendocrine | Seneca Valley V... | 18 Years - | Neotropix | |
| Prospective Study of Clinically Nonfunctioning Pituitary Adenomas | NCT01556230 | Pituitary Adeno... Pituitary Tumor | Surgical interv... Radiotherapy fo... | 18 Years - | Columbia University | |
| Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma | NCT00780663 | Neuroendocrine ... Carcinoid Tumor | Quarfloxin | 18 Years - | Cylene Pharmaceuticals | |
| Evaluation of Methods for the Determination of Chromogranin A in Routine Blood Samples | NCT01216267 | Neuroendocrine ... | Lansoprazole lansoprazole | 18 Years - 70 Years | University of Western Ontario, Canada | |
| Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET) | NCT01169649 | PANCREAS Neuroendocrine | MK-2206 | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Study of Axitinib in Advanced Carcinoid Tumors | NCT01435122 | Carcinoid Tumor | Axitinib | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors | NCT02549937 | Tumors | surufatinib | 18 Years - | Hutchmed | |
| Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors | NCT02611024 | Advanced Solid ... Glioblastoma Soft Tissue Sar... Endometrial Car... Epithelial Ovar... Mesothelioma Gastroenteropan... SCLC Gastric Carcino... Pancreatic Aden... Colorectal Carc... Neuroendocrine ... | Lurbinectedin Irinotecan | 18 Years - | PharmaMar | |
| A Study of Axitinib in Advanced Carcinoid Tumors | NCT01435122 | Carcinoid Tumor | Axitinib | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Safety and Efficacy of Atiprimod Treatment for Patients With Low to Intermediate Grade Neuroendocrine Carcinoma | NCT00388063 | Neuroendocrine ... | Atiprimod | 18 Years - | Callisto Pharmaceuticals | |
| Efficacy Study of Sorafenib and Cyclophosphamide to Treat Neuroendocrine Tumors | NCT00605566 | Neuroendocrine ... | Sorafenib Cyclophosphamid... | 18 Years - | University Health Network, Toronto | |
| Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma | NCT00780663 | Neuroendocrine ... Carcinoid Tumor | Quarfloxin | 18 Years - | Cylene Pharmaceuticals | |
| Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy | NCT00363051 | Islet Cell Carc... Neuroendocrine ... Neuroendocrine ... Pancreatic Neop... | Everolimus 10 m... Octreotide Depo... | 18 Years - | Novartis | |
| Neuroendocrine Tumors - Patient Reported Outcomes | NCT05064150 | Neuroendocrine ... Gastroenteropan... Lung Neuroendoc... Neuroendocrine ... | 18 Years - | University of Iowa | ||
| A Study to Assess PV-10 Chemoablation of Cancer of the Liver | NCT00986661 | Cancer Metastat... Hepatocellular ... Metastatic Mela... Metastatic Ocul... Metastatic Uvea... Metastatic Lung... Metastatic Colo... Metastatic Colo... Metastatic Brea... Metastatic Panc... | PV-10 (10% rose... | 18 Years - | Provectus Pharmaceuticals | |
| Evaluation of Methods for the Determination of Chromogranin A in Routine Blood Samples | NCT01216267 | Neuroendocrine ... | Lansoprazole lansoprazole | 18 Years - 70 Years | University of Western Ontario, Canada | |
| A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors | NCT04644315 | Neoplasms Colorectal Neop... Melanoma Pancreatic Neop... Sarcoma Ovarian Neoplas... Brain Neoplasms Thyroid Neoplas... Neuroendocrine ... Cholangiocarcin... Salivary Gland ... Head and Neck N... Thyroid Cancer,... Lymphoma, Large... Neoplasms by Si... Respiratory Tra... Thoracic Neopla... Respiratory Tra... Carcinoma, Bron... Bronchial Neopl... Intestinal Neop... Gastrointestina... Digestive Syste... Digestive Syste... Gastrointestina... Colonic Disease... Intestinal Dise... Central Nervous... | Alectinib | 18 Years - | Hoffmann-La Roche | |
| Safety Study of Seneca Valley Virus in Patients With Solid Tumors With Neuroendocrine Features | NCT00314925 | Carcinoid Neuroendocrine | Seneca Valley V... | 18 Years - | Neotropix | |
| Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres | NCT02859064 | Neuroendocrine ... Gastrointestina... Carcinoid Tumor... | Lanreotide Y-90 microspher... | 18 Years - | SCRI Development Innovations, LLC | |
| Natural History of Familial Carcinoid Tumor | NCT00646022 | Carcinoid | [18F]-DOPA | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| RAD001 and Erlotinib in Patients With Neuroendocrine Tumors | NCT00843531 | Neuroendocrine ... | RAD001 erlotinib | 18 Years - | University of California, San Francisco | |
| A Study of Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid Tumors | NCT05268666 | Locally Advance... Metastatic Soli... | JBI-802 | 18 Years - | Jubilant Therapeutics Inc. | |
| Safety and Efficacy of Atiprimod Treatment for Patients With Low to Intermediate Grade Neuroendocrine Carcinoma | NCT00388063 | Neuroendocrine ... | Atiprimod | 18 Years - | Callisto Pharmaceuticals | |
| Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor | NCT00412061 | Carcinoid Tumor Malignant Carci... | Octreotide Placebo Everolimus | 18 Years - | Novartis | |
| A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers | NCT02132468 | Neuroendocrine ... | fosbretabulin t... | 18 Years - | Mateon Therapeutics | |
| EPO906 in Carcinoid and Other Neuroendocrine Tumors | NCT00050349 | Carcinoid Neuroendocrine ... | EPO906 epothilo... | 18 Years - | Novartis | |
| Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1 | NCT02355535 | Solid Tumor Pancreatic Neur... Neuroendocrine ... | PAC-1 | 18 Years - 85 Years | Vanquish Oncology, Inc. | |
| Safety and Efficacy of Atiprimod Treatment for Patients With Low to Intermediate Grade Neuroendocrine Carcinoma | NCT00388063 | Neuroendocrine ... | Atiprimod | 18 Years - | Callisto Pharmaceuticals | |
| 68Ga-DOTATATE PET Scan in Neuroendocrine Cancer | NCT01396382 | Neuroendocrine ... | 68Ga-DOTATATE P... | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors | NCT04644315 | Neoplasms Colorectal Neop... Melanoma Pancreatic Neop... Sarcoma Ovarian Neoplas... Brain Neoplasms Thyroid Neoplas... Neuroendocrine ... Cholangiocarcin... Salivary Gland ... Head and Neck N... Thyroid Cancer,... Lymphoma, Large... Neoplasms by Si... Respiratory Tra... Thoracic Neopla... Respiratory Tra... Carcinoma, Bron... Bronchial Neopl... Intestinal Neop... Gastrointestina... Digestive Syste... Digestive Syste... Gastrointestina... Colonic Disease... Intestinal Dise... Central Nervous... | Alectinib | 18 Years - | Hoffmann-La Roche | |
| Natural History of Familial Carcinoid Tumor | NCT00646022 | Carcinoid | [18F]-DOPA | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres | NCT02859064 | Neuroendocrine ... Gastrointestina... Carcinoid Tumor... | Lanreotide Y-90 microspher... | 18 Years - | SCRI Development Innovations, LLC | |
| DOTA-TOC in Metastasized Neuroendocrine Tumors | NCT00978211 | Neuroendocrine ... | DOTA-TOC Treatm... | - | University Hospital, Basel, Switzerland | |
| Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease | NCT00690430 | Symptomatic Ref... | Pasireotide Octreotide | 18 Years - | Novartis | |
| EPO906 in Carcinoid and Other Neuroendocrine Tumors | NCT00050349 | Carcinoid Neuroendocrine ... | EPO906 epothilo... | 18 Years - | Novartis | |
| Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET) | NCT01169649 | PANCREAS Neuroendocrine | MK-2206 | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Neuroendocrine Tumors - Patient Reported Outcomes | NCT05064150 | Neuroendocrine ... Gastroenteropan... Lung Neuroendoc... Neuroendocrine ... | 18 Years - | University of Iowa | ||
| Evaluation of Methods for the Determination of Chromogranin A in Routine Blood Samples | NCT01216267 | Neuroendocrine ... | Lansoprazole lansoprazole | 18 Years - 70 Years | University of Western Ontario, Canada | |
| Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs) | NCT03591731 | Neuroendocrine ... | Nivolumab Ipilimumab | 18 Years - | Intergroupe Francophone de Cancerologie Thoracique | |
| Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1 | NCT02355535 | Solid Tumor Pancreatic Neur... Neuroendocrine ... | PAC-1 | 18 Years - 85 Years | Vanquish Oncology, Inc. | |
| Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease | NCT00690430 | Symptomatic Ref... | Pasireotide Octreotide | 18 Years - | Novartis | |
| A Study to Assess PV-10 Chemoablation of Cancer of the Liver | NCT00986661 | Cancer Metastat... Hepatocellular ... Metastatic Mela... Metastatic Ocul... Metastatic Uvea... Metastatic Lung... Metastatic Colo... Metastatic Colo... Metastatic Brea... Metastatic Panc... | PV-10 (10% rose... | 18 Years - | Provectus Pharmaceuticals | |
| Capecitabine ON Temozolomide Radionuclide Therapy Octreotate Lutetium-177 NeuroEndocrine Tumours Study | NCT02358356 | Midgut Neuroend... Pancreatic Neur... | octreotate Capecitabine Temozolomide | 18 Years - | Australasian Gastro-Intestinal Trials Group | |
| Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor | NCT00412061 | Carcinoid Tumor Malignant Carci... | Octreotide Placebo Everolimus | 18 Years - | Novartis | |
| Activity and Safety of Everolimus+Octreotide LAR+Metformin in Advanced Pancreatic Well-differentiated NETs | NCT02294006 | Well Differenti... | Everolimus plus... | 18 Years - | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | |
| XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer | NCT05005728 | Metastatic Cast... | vudalimab + car... vudalimab + ola... vudalimab monot... vudalimab + doc... vudalimab + cab... | 18 Years - | Xencor, Inc. | |
| Activity and Safety of Everolimus+Octreotide LAR+Metformin in Advanced Pancreatic Well-differentiated NETs | NCT02294006 | Well Differenti... | Everolimus plus... | 18 Years - | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
